ArticleNature immunology2010
Integrins limit the Toll.
Article in Nature immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Complement receptor 3-dependent engagement byOpen biology · 2024Article
- Differential effects of dexmedetomidine on Gram-positive and Gram-negative bacterial killing and phagocytosis.International immunopharmacology · 2023Article
- CD11a regulates hematopoietic stem and progenitor cells.Frontiers in immunology · 2023Article
- Spatio-Temporal Changes of Extracellular Matrix (ECM) Stiffness in the Development of the LeechInternational journal of molecular sciences · 2022Article
- CD11b suppresses TLR activation of nonclassical monocytes to reduce primary graft dysfunction after lung transplantation.The Journal of clinical investigation · 2022Article
- CD11b agonists offer a novel approach for treating lupus nephritis.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Bim Expression Promotes the Clearance of Mononuclear Phagocytes during Choroidal Neovascularization, Mitigating Scar Formation in Mice.Life (Basel, Switzerland) · 2022Article
- A Genetic Model of Constitutively Active Integrin CD11b/CD18.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Airway epithelial ITGB4 deficiency in early life mediates pulmonary spontaneous inflammation and enhanced allergic immune response.Journal of cellular and molecular medicine · 2020Article
- CR4 Signaling Contributes to a DC-Driven Enhanced Immune Response Against Complement-Opsonized HIV-1.Frontiers in immunology · 2020Article
- Monoclonal Antibody to CD14, TLR4, or CD11b: Impact of Epitope and Isotype Specificity on ROS Generation by Human Granulocytes and Monocytes.Oxidative medicine and cellular longevity · 2020Review
- Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.Science translational medicine · 2019Article
- Significance of Complement System in Ischemic Stroke: A Comprehensive Review.Aging and disease · 2019Review
- Impact of CD14 on Reactive Oxygen Species Production from Human Leukocytes Primed byOxidative medicine and cellular longevity · 2019Article
- Integrins promote axonal regeneration after injury of the nervous system.Biological reviews of the Cambridge Philosophical Society · 2018Review
- CD11b Activity Modulates Pathogenesis of Lupus Nephritis.Frontiers in medicine · 2018Review
- CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus.The Journal of clinical investigation · 2017Article
- CD11b is protective in complement-mediated immune complex glomerulonephritis.Kidney international · 2015Article
- Article
- Involvement of Toso in activation of monocytes, macrophages, and granulocytes.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20644576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.